Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
Simultaneously, the depletion of opsonin-based proteins in the corona extends their circulation time in the blood, as observed clinically.
- Simultaneously, the depletion of opsonin-based proteins in the corona extends their circulation time in the blood, as observed clinically.
- “When we invented the electro-crystal-chemical method to grow clean-surfaced, highly faceted gold nanocrystals, we certainly had catalytic optimization in mind.
- However, we also understood that the protein corona can control the location of our nanocrystals in vivo.
- A Phase 3 registrational clinical trial of CNM-Au8 for the treatment of the progressive neurodegenerative disease, amyotrophic lateral sclerosis, is presently planned to launch in 2024.